Blair William & CO Cti Biopharma Corp Transaction History

Blair William & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$4.45 - $6.17 $194,843 - $270,153	-43,785 Reduced 24.85%	132,413 $795,000
Q1 2022 May 13, 2022	SELL	$1.9 - $5.23 $190,000 - $523,000	-100,000 Reduced 36.21%	176,198 $823,000
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.86 $144,000 - $286,000	100,000 Added 56.75%	276,198 $685,000
Q3 2021 Nov 12, 2021	BUY	$2.25 - $3.18 $225,000 - $318,000	100,000 Added 131.24%	176,198 $520,000
Q4 2020 Feb 09, 2021	SELL	$2.48 - $3.8 $32 - $49	-13 Reduced 0.02%	76,198 $245,000
Q1 2020 May 11, 2020	BUY	$0.69 - $1.54 $17,250 - $38,500	25,000 Added 48.82%	76,211 $70,000
Q3 2019 Nov 12, 2019	BUY	$0.64 - $0.92 $8 - $11	13 Added 0.03%	51,211 $43,000
Q2 2018 Aug 13, 2018	BUY	$3.81 - $5.26 $195,064 - $269,301	51,198 New	51,198 $255,000
Q1 2018 May 15, 2018	SELL	$2.7 - $4.06 $138,234 - $207,863	-51,198 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$2.47 - $3.34 $126,459 - $171,001	51,198	51,198 $137,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.